What is CRBP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.10B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CRBP?

P/E (TTM) is n/a and 52-week range is $5.13 to $20.56 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CRBP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CRBP?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-4.40B, EPS (TTM) near $-6.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Corbus Pharmaceuticals Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Norwood, Massachusetts, US, 18.5M shares outstanding, ISIN US21833P3010 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Corbus Pharmaceuticals Holdings Inc

$CRBP

Health Care · Biotechnology

IR Run Scenarios

$5.38

+2.09%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Employees

Website

www.corbuspharma.com/

IPO

2014-10-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)